PubRank

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Clinical Trial ID NCT01828112

PubWeight™ 21.99‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01828112

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015 1.67
2 ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014 1.48
3 Novel ALK inhibitors in clinical use and development. J Hematol Oncol 2015 1.24
4 Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer. Onco Targets Ther 2014 1.19
5 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
6 Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014 1.05
7 Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2013 1.03
8 A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014 0.93
9 Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014 0.92
10 ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014 0.89
11 Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Oncologist 2016 0.87
12 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
13 Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. Ther Adv Med Oncol 2016 0.83
14 Recent advances in personalized lung cancer medicine. Per Med 2014 0.82
15 Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer. Cancer Manag Res 2016 0.81
16 Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol 2015 0.80
17 Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016 0.79
18 New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib. Ther Clin Risk Manag 2016 0.77
19 Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res 2016 0.76
20 Cross-over-it's a feature, not a bug. Ann Oncol 2015 0.75
21 Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. Pharmgenomics Pers Med 2015 0.75
22 Crizotinib resistance: implications for therapeutic strategies. Ann Oncol 2016 0.75
23 Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. J Thorac Dis 2016 0.75
24 Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. Onco Targets Ther 2016 0.75
Next 100